SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Immunomedics (IMMU)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Josh C. Pleasure, M.D. who wrote (46)10/2/1996 11:52:00 PM
From: WWS   of 371
 
Josh, yes, I saw the SBIR grants. While it is good to see that IMMU is focusing on the future, I wonder whether nonhodgkins lymphoma is the the best choice of targets. Recent Phase III results report by IDEC Pharmaceutical and Coulter have both shown very positive results, and both techniques utilize monoclonal antibodies as IMMU is also proposing to do. By the time that IMMU gets there, most of the money might already be off the table.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News